Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
What Clinical Trials Show In large obesity trials: Average weight loss is ~15% of starting body weight with semaglutide 2.4 mg Average weight loss is ~2022% of starting body weight with tirzepatide 15 mg The majority of weight loss occurs within the first year of treatment Plateaus are common after significant weight reduction Some people lose more, some less but a flattening of the weight-loss curve is expected , especially after meaningful progress has already occurred
Retatrutide produces higher rates of nausea (43% vs 20-47%), diarrhea (33% vs lower), and vomiting (21% vs lower) at their respective maintenance doses
Gallbladder problems: Symptoms include upper abdominal pain, fever, jaundice, or clay-colored stools
Nutrimicrobiomics 3
